Free Trial
OTCMKTS:INBP

Integrated BioPharma (INBP) Stock Price, News & Analysis

Integrated BioPharma logo
$0.29 -0.03 (-9.29%)
(As of 11/7/2024 ET)

About Integrated BioPharma Stock (OTCMKTS:INBP)

Key Stats

Today's Range
$0.29
$0.30
50-Day Range
$0.19
$0.35
52-Week Range
$0.16
$0.35
Volume
21,380 shs
Average Volume
10,968 shs
Market Capitalization
$8.82 million
P/E Ratio
29.33
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Receive INBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Integrated BioPharma and its competitors with MarketBeat's FREE daily newsletter.

INBP Stock News Headlines

Integrated Biopharma Inc (INBP)
Integrated BioPharma, Inc. (INBP)
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
What Is a Vertically Integrated Business Model?
See More Headlines

INBP Stock Analysis - Frequently Asked Questions

Integrated BioPharma's stock was trading at $0.2452 at the beginning of 2024. Since then, INBP shares have increased by 19.5% and is now trading at $0.2930.
View the best growth stocks for 2024 here
.

Integrated BioPharma, Inc. (OTCMKTS:INBP) released its quarterly earnings results on Friday, September, 20th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm earned $12.75 million during the quarter. Integrated BioPharma had a net margin of 0.22% and a trailing twelve-month return on equity of 0.59%.

Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP).

Company Calendar

Last Earnings
9/20/2024
Today
11/08/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:INBP
Employees
150
Year Founded
N/A

Profitability

Net Income
$110,000.00
Pretax Margin
0.53%

Debt

Sales & Book Value

Annual Sales
$50.32 million
Cash Flow
$0.04 per share
Book Value
$0.64 per share

Miscellaneous

Free Float
9,873,000
Market Cap
$8.82 million
Optionable
Not Optionable
Beta
0.62
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:INBP) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners